Search

International audience; Following the events of September 11, 2001, in the United States, world public awareness for possible terrorist attacks on water supply systems has increased dramatically. Among the different threats for a water distribution system, the most difficult to address is a deliberate chemical or biological contaminant injection, due to both the uncertainty of the type of injected contaminant and its consequences, and the uncertainty of the time and location of the injection. An online contaminant monitoring system is considered as a major opportunity to protect against the impacts of a deliberate contaminant intrusion. However, although optimization models and solution algorithms have been developed for locating sensors, little is known about how these design algorithms compare to the efforts of human designers, and thus, the advantages they propose for practical design of sensor networks. To explore these issues, the Battle of the Water Sensor Networks (BWSN) was undertaken as part of the 8th Annual Water Distribution Systems Analysis Symposium, Cincinnati, Ohio, August 2729, 2006. This paper summarizes the outcome of the BWSN effort and suggests future directions for water sensor networks research and implementation.

Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE 9 is an observational retrospective multicentric study which aimed to describe the clinical outcome of patients with HR + /HER2 + ABC who received the combination of Fulvestrant (F) and Trastuzumab (T) as part of their routine treatment at 10 Italian Institutions. Results: Eighty-seven patients were included. Median age was 63 (range, 35–87) years. The median number of previous treatments was 3 (range, 0–10) and F and T were administered as ≥ 3rd line in 67 patients. Among the 86 evaluable patients, 6 (6.9%) achieved CR, 18 (20.7%) PR, and 44 (50.6%) had SD ≥ 24 weeks with an overall CBR of 78.2%. At a median follow-up of 33.6 months, mPFS of the entire cohort was 12.9 months (range, 2.47–128.67). No difference was observed in mPFS between patients treated after progression or as maintenance therapy (mPFS 12.9 and 13.9 months in 64 and 23 patients, respectively), neither considering the number of previous treatment lines (≤ 3 or < 3). Conclusion: The combination of F and T was active in this cohort at poor prognosis and deserves further investigations possibly in combination with pertuzumab in patients with high ER expression.